Methods of treatment with pre-mixed, ready-to-use...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S400000

Reexamination Certificate

active

07659291

ABSTRACT:
Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

REFERENCES:
patent: 3985758 (1976-10-01), Murakami
patent: 4711902 (1987-12-01), Semo
patent: 4880823 (1989-11-01), Ogawa et al.
patent: 4940556 (1990-07-01), MacFarlane
patent: 5079237 (1992-01-01), Husu et al.
patent: 5164405 (1992-11-01), McFarlane et al.
patent: 5198226 (1993-03-01), MacFarlane
patent: RE34618 (1994-05-01), Ogawa
patent: 5376645 (1994-12-01), Stella
patent: 5519012 (1996-05-01), Fercej-Temeljotov
patent: 5904929 (1999-05-01), Uekama
patent: 6595926 (2003-07-01), Laragh
patent: 2007/0112041 (2007-05-01), Bhowmick
patent: 2007/0244166 (2007-10-01), Gupta
patent: 2007/0249689 (2007-10-01), Duncan
patent: 0149475 (1985-07-01), None
patent: 0162705 (1985-11-01), None
patent: 2228412 (1990-08-01), None
patent: WO 2001/07086 (2001-02-01), None
Kaiser, Barb, et al., Solutions to Health Care Waste: Life-Cycle Thinking and “green” purchasing, Enviromental Health Perspectives, vol. 109, No. 3, Mar. 2001, pp. 1-4.
Pomponio, R. et al., Photostability studies on nicardipine-cyclodextrin complexes by capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis 35 (2004) 267-275.
Yang et al., “Nicardipine versus nitroprusside infusion as antihypertensive therapy in hypertensive emergencies,” J. Int Med Research, vol. 32(2):118-123 (Mar.-Apr. 2004).
Atlee et al., “The use of esmolol, nicardipine, or their combination to blunt hemodynamic changes after laryngoscopy and tracheal intubation,” Anesth Analg, vol. 90:280-285 (Feb. 2000).
Aya et al., “Intravenous nicardipine for severe hypertension in pre-eclampsia—effects of an acute treatment on mother and foetus,” Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999).
Cheung et al., “Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function,” Anesth Analg, vol. 89:1116-1123 (Nov. 1999).
Colson et al., “Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery,” Act Anaesthesiol Scand., vol. 42(9):1114-1119 (Oct. 1998).
Elatrous et al., “Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol,” Intensive Care Med., vol. 28(9):1281-1286 (Jul. 26, 2002).
Fernandes et al., “Physiochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds,” Eur. J. of Pharma. Sci. 15: pp. 79-88, 2002.
Flynn et al., “Intravenous nicardipine for treatment of severe hypertension in children,” J Pediatr., vol. 139(1):38-43 (Jul. 2001).
Kwak et al., “Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary artery bypass graft surgery,” J Int Med Res, vol. 32:342-350 (Jul.-Aug. 2004).
Vincent et al., “Intravenous nicardipine in the treatment of postoperative arterial hypertension,” J Cardiothorac Vasc Anesth, vol. 11(2):160-164 (Apr. 1997).
Non Final Office Action for U.S. Appl. No. 11/737,067, dated Oct. 29, 2008.
PDL Biopharma, Inc.; “Cardene IV (nicardipine hydrochloride),” Product Insert, Jan. 2006, USA.
Sweetana and Akers, “Solubility principles and practices for parenteral drug dosage form development,” PDAJ Pharmaceutical Science & Technology, 50(5):330-342 (1996).
Zhang et al., “The use of nicardipine for electroconvulsive therapy: a dose-ranging study,” Anesth Analg, vol. 100:378-381 (Feb. 2005).
Endoh et al., “Effects of nicardipine-, nitroglycerin-, and prostaglandin E1-induced hypotension on human cerebrovascular carbon dioxide reactivity during propofol-fentanyl anesthesia,” J Clin Anesth, vol. 11(7):545-549 (Nov. 1999).
Bernard et al., “Long-term hypotensive technique with nicardipine and nitroprusside during isoflurane anesthesia for spinal surgery,” Anesth Analg., vol. 75(2):179-185 (Aug. 1992).
Chen et al., “The comparative potentcy of intravenous nicardipine and verapamil on the cardiovascular response to tracheal intubation,” Acta Anaesthesiol Sin., vol. 34(4):197-202 (Dec. 1996).
Song et al., “Optimal dose of nicardipine for maintenance of hemodynamic stability after tracheal intubation and skin incision,” Anesth Analg, vol. 85:1247-1251 (Dec. 1997).
Cheung et al., “Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine,” Am Heart J., vol. 119(2 Pt 2):438-442 (Feb. 1990).
Yalkowsky et al., “Formulation-related problems associated with intravenous drug delivery,” J Pharm Sciences, vol. 87(7):787-796 (Jul. 1998).
Maurin et al., “Solubilization of nicardipine hydrochloride via complexation and salt formation,” J Pharm Sciences, vol. 83(10):1418-1420 (Oct. 1994).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of treatment with pre-mixed, ready-to-use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment with pre-mixed, ready-to-use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment with pre-mixed, ready-to-use... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4172036

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.